Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori.
Sixty consecutive patients with endoscopically proven duodenal ulcers were given colloidal bismuth subcitrate tablets either as 120 mg q.d.s. or 240 mg b.d., in a randomized single-blind study. The efficacy of each regimen was determined by endoscopic examination and antral biopsy at 4 weeks; if the ulcer remained unhealed, treatment was continued and endoscopy repeated at 8 weeks. The ulcer-healing efficacy of the two regimens was identical; however, in the four times daily group only 27% remained Campylobacter pylori positive after 8 weeks of treatment compared with 58% of the twice-daily group. Similarly, only 21% of twice daily patients were free of histological gastritis compared with 42% of the four times daily patients.
Coghlan
J
J
Department of Gastroenterology, Meath Hospital, Dublin, Republic of Ireland.
Hutchinson
L
L
Gilligan
D
D
McKenna
D
D
Keane
C
C
Sweeney
E
E
O'Morain
C
C
D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003102:Colloids; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005756:Gastritis / Q000188:drug therapy / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method
D000897:Anti-Ulcer Agents; D003102:Colloids; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate